Hepatitis C drug, Mavyret, approved to treat children
by Press Release from Outbreak News Today on (#4E76S)
The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously approved to treat HCV in adults in 2017. "Direct-acting antiviral drugs reduce the amount of HCV in the body by preventing the virus from ["]
The post Hepatitis C drug, Mavyret, approved to treat children appeared first on Outbreak News Today.